| Literature DB >> 35743214 |
Joonho Shin1, Atanu Naskar1, Dongjoon Ko2, Semi Kim2, Kwang-Sun Kim1.
Abstract
Owing to the rapid spread of antibiotic resistance among Staphylococcus species, effective and low-risk alternatives to antibiotics are being actively searched. Thymol (THO), the most abundant component of the oil extracted from thyme, can be considered as a natural antibacterial alternative. However, the low antibacterial activity and non-selectivity of THO limit its usage as a universal anti-Staphylococcus agent. Herein, we report the bioconjugation of THO with ZnO nanoparticle (ZO), which resulted in the TZ nanocomposite (NC), as a potent and selective antibacterial agent against Staphylococcus species, particularly S. epidermidis. The cell-free supernatant (CFS) of ATCC 25923 cultures was employed for the production of TZ NC. Successful production of TZ NC was confirmed via X-ray diffraction (XRD), Fourier-transform infrared (FT-IR) spectroscopy, and ultraviolet-visible (UV-Vis) studies. TZ NC had selective efficacy against Staphylococcus species, with MIC values 2-32-fold lower than THO. The antibacterial mechanisms of TZ NC are proposed to involve membrane rupture, suppression of biofilm formation, and modulation of new cell wall and protein-synthesis-associated cellular pathways. Its biocompatibility against HCT116 cells was also checked. Our findings suggest that the TZ nanocomposite could improve the selectivity and bactericidal activity of THO against target species.Entities:
Keywords: Staphylococcus; antimicrobial; biocompatibility; selectivity; thymol
Mesh:
Substances:
Year: 2022 PMID: 35743214 PMCID: PMC9224476 DOI: 10.3390/ijms23126770
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1X-ray diffraction (XRD) patterns of the ZO and TZ NC samples.
Figure 2(a) UV–vis spectrum of THO, ZO, and TZ NC samples. Inset shows the enlarged spectrum (as marked) of TZ NC sample. (b) FT-IR spectrum of THO and TZ NC samples.
Minimum inhibitory concentrations (MICs) of ZO, THO, and TZ NC against Gram-negative E. coli and Gram-positive Staphylococcus strains.
| Species | Strain Type | Strain Identification Number 1 | Resistant Antibiotics 2 | MIC | ||
|---|---|---|---|---|---|---|
| ZO | THO | TZ | ||||
|
| Type | ATCC 25922 | None | >500 | 500 | >500 |
| MDR | ATCC BAA-2452 | AMI, AMP, AZT, CEF, CTX, ETP, GEN, IMP, MER, PIP, TIC, TOB | >500 | >500 | >500 | |
| ATCC BAA-2469 | AMI, AMP, AZT, CEF, CIP, CTX, ETP, GEN, IMP, MER, NAL, NOR, PIP, TIC, TOB | >500 | >500 | >500 | ||
| ATCC BAA-2471 | AMP, AZT, CEF, CIP, CTX, ETP, GEN, IMP, MER, NAL, NOR, PIP, TIC, TOB | >500 | >500 | >500 | ||
|
| Type | ATCC 25923 | None | >500 | >500 | 62.5 |
| MDR 3 | MRSA1 | MET, OXA | >500 | >500 | 250 | |
| MRSA2 | MET, OXA | >500 | >500 | 500 | ||
| MRSA3 | MET, OXA | >500 | >500 | 125 | ||
| MRSA4 | MET, OXA | >500 | >500 | >500 | ||
|
| Type | ATCC 14990 | None | >500 | >500 | 15.6 |
| KCTC 13171 | None | >500 | >500 | 31.3 | ||
| MDR 4 | ATCC 12228 | STR, AMP, PEN | >500 | >500 | 15.6 | |
|
| Type | ATCC 27836 | None | >500 | >500 | 250 |
1 ATCC and KCTC represent American Type Culture Collection (https://www.atcc.org/; accessed on 17 June 2022) and Korean Collection for Type Cultures (https://kctc.kribb.re.kr/; accessed on 17 June 2022), respectively. 2 Acronyms: AMI, Amikacin; AMP, Ampicillin; AZT, Aztreonam; CEF, Cefepime; CTX, Cefotaxime; CIP, Ciprofloxacin; ETP, Ertapenem; GEN, Gentamicin; IMP, Imipenem; MER, Meropenem; MET, Methicillin; NAL, Nalidixic acid; NOR, Norfloxacin; OXA, Oxacillin; STR, Streptomycin; PEN, Penicillin; PIP, Piperacillin; TIC, Ticarcillin; TOB, Tobramycin. 3 The strain information is provided in a previous report [34]. 4 ATCC 12228 has been studied to understand the multiple antibiotic resistant potential mediated by efflux pump [35] and antibiotic exposures [36].
Figure 3Growth curve analysis. (i) Growth of S. epidermidis strain (ATCC 14990) at an absorbance of 600 nm (OD600) following treatment with different concentrations of (a) ZO, (b) THO, or (c) TZ NC for 20 h. The growth curve data were plotted as average values with standard deviations of n = 3 using SigmaPlot (ver. 12.5) (Systat Software Inc., San Jose, CA, USA). (d) Cell viability. (ii). Growth of MDR S. epidermidis strain (ATCC 12228) at OD600 following treatment with different concentrations of (a) ZO, (b) THO, or (c) TZ NC for 20 h. The growth curve data were plotted as the average values with standard deviations of n = 3 using SigmaPlot (ver. 12.5) (Systat Software Inc., San Jose, CA, USA). (d) Cell viability. A fraction of cells from the end point of the growth curves were spotted on LB agar plates and incubated at 37 °C for 24 h. The plate images were captured using ChemiDocTM MP (Bio-Rad, Hercules, CA, USA) and ImageLabTM Software (ver.5.2.1, Bio-Rad, Hercules, CA, USA). One of the representatives from n = 3 is presented.
Figure 4Biofilm formation assays. Relative biofilm formation (OD595/OD600) was determined for cells of (a) MDR S. epidermidis (ATCC 12228) and (b) type S. aureus (ATCC 25923) strains under the presence or absence of ZO, THO, and TZ NC. The values shown in the graphs represent average values with standard deviation of n = 10 experiments (p < 0.05). The data were analyzed using GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA).
Figure 5Cell morphology analysis. Scanning electron microscopy (SEM) images of MDR S. epidermidis cells of ATCC 12228 without (a–d) treatment with either 1/4 MIC (e–h) or 1/2 MIC (i–l) of TZ NC, respectively were shown. No membrane disruption was shown in 1/4 MIC of TZ NC treated cells (e–h) compared to non-treated cells. The whole membrane was aggregated with TZ NC in cells treated with 1/2 MIC of TZ NC (i–l), inducing partial membrane rupture.
Minimum inhibitory concentration (MIC) of antibiotics owing to TZ NC against the type S. epidermidis strain.
| Antibiotics | Acronym | Subclass | MIC (μg·mL−1) 1 | |
|---|---|---|---|---|
| −TZ | +TZ | |||
| Ampicillin | AMP | β-lactam | 0.125 | 0.0625 |
| Chloramphenicol | CHL | Amphenicol | >4 | 4 |
| Ciprofloxacin | CIP | Fluoroquinolone | <0.25 | <0.25 |
| Clindamycin | CLI | Lincosamide | <0.125 | <0.125 |
| Daptomycin | DAP | Cyclic lipopeptide | >1 | 1 |
| Erythromycin | ERY | Macrolide | 0.5 | 0.25 |
| Gentamicin | GEN | Aminoglycoside | <0.5 | <0.5 |
| Levofloxacin | LEVO | Fluoroquinolone | 0.25 | 0.125 |
| Linezolid | LZD | Oxazolidinone | >2 | 1 |
| Moxifloxacin | MXF | Fluoroquinolone | 0.125 | 0.125 |
| Nitrofurantoin | NIT | Nitrofuran | 16 | <8 |
| Oxacillin | OXA+ | β-lactam | 0.125 | 0.125 |
| Penicillin | PEN | β-lactam | 0.25 | 0.0625 |
| Quinupristin/ | SYN | Lincosamide | <0.125 | <0.125 |
| Rifampin | RIF | Rifampicin | <0.125 | <0.125 |
| Streptomycin | STR | Aminoglycoside | <250 | <250 |
| Tetracycline | TET | Tetracycline | >4 | >4 |
| Tigecycline | TGC | Tetracycline | 0.125 | 0.03 |
| Trimethoprim/sulfamethoxazole | SXT | Co-trimoxazole | 0.25/4.75 | 0.5/9.5 |
| Vancomycin | VAN | Glycopeptide | 2 | 2 |
1 MIC values of the antibiotics were determined using SensititreTM Gram Positive MIC plate (Cat. No. GPALL1F, Thermo Fisher Scientific, Waltham, MA, USA) with a total volume of 200 μL. Three independent experiments were performed with ATCC 14990 cells using the 96-well platform as shown in Figure S7. Antibiotics with enhanced antibacterial activity owing to TZ NC are indicated in bold.
Figure 6Biocompatibility assays. WST assays were performed to determine the viability of HCT116 cells in the presence of various concentrations of ZO, THO, and TZ NC after 24 h. The values shown in the graphs are averages of n = 3 with standard deviation (p < 0.05). Data were analyzed using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA).